Let's look at a strategy for Cardiff Oncology, whose shares got snagged in the biotech selloff in early 2022.
Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.
Here's why I'm going with AMN Healthcare for the remainder of the year.
As M&A investments could hit $400 billion this year, watch for buys in health technology and data, biotech, pharma and medical devices.
We're seeing a group move in pharma right now, so let's sort it out, pill by pill.
Let's take a look at 2 charts.
Perrigo hit some bumps, but it offers deep value and dividend growth.
A potential breakthrough in Alzheimer's. A new device for blood pressure. More vaccines. These are opportunities to cheer in a time of turmoil.
EBIX offers extensive potential gains while downside appears small.
After finding success in treatment for epilepsy and other conditions, some in the industry are focusing on autism spectrum disorder.